Skip to main content

Table 3 Acute adverse events

From: Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial

AEs N = 108 (%)
Grade 1–2 Grade 3 Grade 4
Hematological
 Leukopenia 32 (29.6%) 26 (24.1%) 35 (32.4%)
 Neutropenia 25 (23.1%) 23 (21.3%) 40 (37.0%)
 Anemia 65 (60.2%) 10 (9.3%) 1 (0.9%)
 Thrombocytopenia 69 (63.9%) 18 (16.7%) 5 (4.6%)
Nonhematological
 Acid reflux/vomiting 58 (53.7%) 0 3 (2.8%)
 Hiccup 30 (27.8%) 0 0
 Fever 12 (11.1%) 0 0
 Hair loss 58 (53.7%) 0 0
 Muscular soreness 23 (21.3%) 0 0
 Neurotoxicity 3 (2.8%) 0 0
Radiation-induced
 Dermatitis 45 (41.7%) 0 0
 Esophagitis 84 (77.8%) 0 0
 Pneumonitis 53 (49.1%) 1 (0.9%) 0